Corticosteroid use in ARDS and its application to evolving therapeutics for coronavirus disease 2019 (COVID-19): A systematic review

Kaitlin M. Landolf¹ | Steven M. Lemieux² | Christina Rose³ | Jackie P. Johnston⁴ © | Christopher D. Adams⁴ | Jerry Altshuler⁵ | Karen Berger⁶ © | Deepali Dixit⁴ | Muhammad K. Effendi⁴ | Mojdeh S. Heavner¹ © | Diana Lemieux⁷ | Audrey J. Littlefield⁶ | Andrea M. Nei⁸ | Kent A. Owusu⁷,⁹ | Marisa Rinehart¹ | Blake Robbins¹⁰ | Ginger E. Rouse⁷ | Melissa L. Thompson Bastin¹⁰ ©

¹Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, Maryland, USA
²Department of Pharmacy, VA Connecticut Healthcare System, West Haven, Connecticut, USA
³Department of Pharmacy Practice, Temple University School of Pharmacy, Philadelphia, Pennsylvania, USA
⁴Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Piscataway, New Jersey, USA
⁵Department of Pharmacy, Hackensack Meridian Health JFK University Medical Center, Edison, New Jersey, USA
⁶Department of Pharmacy Services, Yale New Haven Hospital, New Haven, Connecticut, USA
⁷Department of Pharmacy, New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, USA
⁸Department of Pharmacy Services, Yale New Haven Hospital, New Haven, Connecticut, USA
⁹Department of Pharmacy, Mayo Clinic Hospital – Rochester, Rochester, Minnesota, USA
¹⁰Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, Kentucky, USA

Correspondence
Melissa L. Thompson Bastin, Department of Pharmacy Practice and Administration, University of Kentucky College of Pharmacy, 800 Rose St. H110, Lexington, KY 40536, USA. Email: mlthompson@uky.edu

Abstract
Data regarding the use of corticosteroids for treatment of acute respiratory distress syndrome (ARDS) are conflicting. As the coronavirus disease 2019 (COVID-19) pandemic progresses, more literature supporting the use of corticosteroids for COVID-19 and non-COVID-19 ARDS have emerged. Glucocorticoids are proposed to attenuate the inflammatory response and prevent progression to the fibroproliferative phase of ARDS through their multiple mechanisms and anti-inflammatory properties. The purpose of this systematic review was to comprehensively evaluate the literature surrounding corticosteroid use in ARDS (non-COVID-19 and COVID-19) in addition to a narrative review of clinical considerations of corticosteroid use in these patient populations. OVID Medline and EMBASE were searched. Randomized controlled trials evaluating the use of corticosteroids for COVID-19 and non-COVID-19 ARDS in adult patients on mortality outcomes were included. Risk of bias was assessed with the Risk of Bias 2.0 tool. There were 388 studies identified, 15 of which met the inclusion criteria that included a total of 8877 patients. The studies included in our review reported a mortality benefit in 6/15 (40%) studies with benefit being seen at varying time points of mortality follow-up (ICU survival, hospital, and 28 and 60 days) in the COVID-19 and non-COVID-19 ARDS studies. The two non-COVID19 trials assessing lung injury score improvements found that corticosteroids led to significant improvements with corticosteroid use. The number of mechanical ventilation-free days significantly were found to be increased with the use of corticosteroids in all four studies that assessed this outcome. Corticosteroids are associated with improvements in mortality and ventilator-free days in critically ill patients with both COVID-19 and non-COVID-19 ARDS, and evidence suggests their use should be encouraged in these settings. However, due to substantial differences in the corticosteroid regimens utilized in these trials, questions still remain regarding the optimal corticosteroid agent, dose, and duration in patients with ARDS.
INTRODUCTION

Prior to the coronavirus disease 2019 (COVID-19) pandemic, approximately 10% of patients presenting to the intensive care unit (ICU) were admitted for acute respiratory distress syndrome (ARDS). This estimate has increased subsequent to the pandemic with approximately 33% of patients with COVID-19 developing ARDS. ARDS is a hypoxemic state caused by an inflammatory process resulting in alveolar damage (Figure 1) within 72 h following pulmonary insult. Inflammatory mediators and chemokines are released in response to insult during the exudative phase where cellular injury is propagated by neutrophil accumulation, disrupting alveolar epithelial/endothelial barriers leading to fluid and debris accumulation. In the proliferative phase, restoration of endothelial and epithelial barriers occurs in addition to resorption of alveolar fluid. Progression to the fibrotic phase results in fibrosis of the interstitium and within the alveoli. The mechanism of alveolar damage in both non-COVID-19 and COVID-19 ARDS is thought to be no different based on autopsy and clinical features. Corticosteroids have been explored as a treatment for ARDS due to their anti-inflammatory and anti-fibrotic properties, however, their use in improving clinically meaningful outcomes remains controversial. Herein, we provide a comprehensive review of the literature regarding corticosteroid use in non-COVID-19 and COVID-19 ARDS in addition to a narrative review of clinical considerations for these patient populations.

1.1 Mechanism of corticosteroids in ARDS

Glucocorticoids have potent anti-inflammatory and immunomodulating effects via non-genomic and genomic mechanisms (Figure 2). Cytosolic glucocorticoid–glucocorticoid receptor (GC–GR) complexes directly modulate the transcription of glucocorticoid response elements and inhibit transcription factors nuclear factor-κB (NF-κB) and activating protein-1. Through these mechanisms, glucocorticoids attenuate the production of pro-inflammatory cytokines. They also work synergistically with natural anti-inflammatory cytokines, including IL-4, -10, and -13 and increase the expression of IL-1 receptor antagonist. Glucocorticoids have inhibitory effects on fibrin pathways including inhibition of fibroblast proliferation and collagen deposition through inhibition of cytokines. They stimulate T-cell, eosinophil, and monocyte apoptosis that may naturally work to decrease inflammation in ARDS and inhibit neutrophil activation that may otherwise potentiate inflammation in ARDS. It is postulated that relative glucocorticoid deficiency and unchecked inflammation further worsens inflammation in the setting of ARDS. Through the above mechanisms,

**FIGURE 1** Actions of Corticosteroids in Acute Respiratory Distress Syndrome (ARDS). Panel A depicts a normal alveolus with intact alveolar cell structures and vascular epithelial membrane. Panel B shows alveolar changes following an acute inflammatory insult. Corticosteroids mitigate multiple pathways in the acute state. (1) Reduce extravasation of plasma through the intercellular junction. (2) Inhibit adhesion of neutrophils to the endothelial cell and migration across the capillary wall into the alveoli. (3) Modulation of pro-inflammatory cytokines through genomic and non-genomic pathways. (4) Inhibition of fibroblast proliferation and collagen disposition.
Pharmacology of Glucocorticoids. NF-κB, nuclear factor-kappa B, Hsp, heat shock protein, IκB, inhibitor-kappa B. The three main pathways of glucocorticoid pharmacology include DNA-dependent regulation of anti-inflammatory proteins, non-genomic modulation of inflammation, and direct protein interference of transcription factors such as nuclear factor-kappa B (NF-κB). Corticosteroids diffuse across cell membranes and bind with cytosol-bound glucocorticoid receptors. Activated glucocorticoid-glucocorticoid receptor (GC-GR) complexes trigger both non-genomic and genomic pathways. In the nucleus, the GC-GR complex dimerizes and activates glucocorticoid-responsive elements, stimulating production of mRNA and induction of anti-inflammatory proteins, such as Annexin I. Non-genomic effects are not fully elucidated but are thought to be dose dependent. Inflammatory signals such as tumor necrosis factor-alpha, interleukin-1, microbial pathogens, and viral proteins activate membrane-bound receptors leading to degradation of inhibitor-kappa B and NF-κB release. In the absence of the GC-GR complex, NF-κB binds NF-κB elements in DNA sequences which activates the production of pro-inflammatory mediators and cyclooxygenase 2. The GC-GR complex directly binds NF-κB transcription factors causing repression of mRNA and inflammatory proteins. Adapted from Rhen et al.

**FIGURE 3** Flow diagram of the number of studies included in the systematic review literature search and reasons for study exclusion.

- Records identified through database searching (n=388)
- Records removed before screening: Duplicate records removed (n=28)
- Records screened (n=360)
- Records excluded based on title and abstract (n=336)
- Reports sought for retrieval (n=25)
- Full-text reports assessed for eligibility (n=25)
- Randomized controlled trial included in qualitative synthesis (n=15)
- Full text reports excluded (n=10)
  - Comparator not placebo or standard of care: (n=2)
  - Not diagnosed with ARDS: (n=3)
  - Not an RCT: (n=1)
  - Not prospective: (n=3)
  - Preliminary report: (n=1)
### TABLE 1  Trials of corticosteroids in acute respiratory distress syndrome

| Trial | Study Period | Design | Patient Population |
|-------|--------------|--------|---------------------|
| Bernard et al. N Engl J Med 1987<sup>29</sup> | Jun. 1983–Nov. 1985 | Prospective placebo-controlled RCT, DB, Multicenter (7 centers) N = 99 | Patients with ARDS defined by: 1) $\text{PaO}_2 < 70 \text{ mmHg}$ on 40% oxygen or $\text{PaO}_2$: partial pressure of alveolar $\text{O}_2$ ≤ 0.3; 2) bilateral diffuse infiltrates on chest X-ray compatible with pulmonary edema; and 3) PAWP ≤ 18 mmHg |
| Meduri et al. JAMA 1998<sup>30</sup> | Oct. 1994–Nov. 1996 | Prospective placebo-controlled RCT, DB, Multicenter (6 centers) N = 24 | Patients with ARDS for <3 weeks: 1) defined by AECC; 2) failure to improve LIS by day 7 of MV (LIS ≥ 2.5 and <1 point LIS reduction from day 1); and 3) no evidence of untreated infection |
| Meduri et al. CHEST 2007<sup>32</sup> | Apr. 1997–Apr. 2002 | Prospective placebo-controlled 2:1 RCT, DB, Multicenter (6 centers) N = 91 | Patients with early ARDS (≤ 72 h) defined by AECC while on PEEP |
| ARDS Clinical Trials Network. N Engl J Med 2006<sup>16</sup> | Aug. 1997–Nov. 2003 | Prospective, placebo-controlled RCT, DB, Multicenter (25 centers) N = 180 | ARDS (P:F < 200, bilateral infiltrates) |
| Confalonieri et al. Am J Respir Crit Care Med 2005<sup>31</sup> | Jul. 2000–Mar. 2003 | Prospective placebo-controlled RCT, DB, Multicenter (6 centers) N = 46 | Severe pneumonia based on modified 1993 ATS criteria or 2 of the following: 1) respiratory rate >30 bpm. 2) P:F < 250, 3) chest radiograph bilateral or multilobar involvement, 4) sbp < 90 mmHg, and 5) DBP < 60 mmHg |
| Annane et al. Crit Care Med 2006<sup>35</sup> | Oct. 1995–Feb. 1999 | Post hoc analysis of a placebo controlled RCT, DB, Multicenter (19 ICUs) N = 177 with ARDS | Septic shock-associated early ARDS (P:F < 200, bilateral infiltrates) |
| Timing of Initiation | Intervention | Primary outcome | Other Outcomes |
|---------------------|--------------|----------------|---------------|
| Time from symptoms: | MP 30 mg/kg IV every 6 hrs for 4 doses | No difference in 45-day mortality: 60% MP vs. 63% placebo, \( p = 0.74 \) | No difference in reversal of ARDS: 36% steroids MP vs. 39% placebo, \( p = 0.77 \) |
| 32.5 hrs in MP vs. 28.9 hrs placebo | Duration: 1 day | | |
| Time from MV: 2.8 ± 0.5 hrs MP vs. 1.9 ± 0.4 hrs placebo | | | |
| Unresolving ARDS | MP loading dose of 2 mg/kg, then 2 mg/kg/day days 1 to 14, 1 mg/kg/day days 15 to 21, 0.5 mg/kg/day days 22 to 28, 0.25 mg/kg/day days 29 to 30, and 0.125 mg/kg/day days 31 to 32 | Improvement in LIS by >1 point: 100% MP vs. 25% placebo, \( p < 0.001 \) Survivors of ICU admission: 100% MP vs. 37% placebo, \( p = 0.002 \) | MODS score: 0.7 (0.2) MP vs. 1.8 (0.3) placebo, \( p < 0.001 \) Survivors at hospital discharge in 87% MP vs. 37% placebo, \( p = 0.03 \) |
| (7 days of MV with LIS of 2.5 or greater and less than 1-point reduction from day 1 of ARDS) | Dosed as continuous infusion | | |
| Day 7 | MP IV loading dose of 1 mg/kg, then 1 mg/kg/day days 1 to 14, 0.5 mg/kg/day days 15 to 21, 0.25 mg/kg/day days 22 to 25, and 0.125 mg/kg/day days 26 to 28 | Improvement in LIS \(^{11} \) or extubation by study day 7: 69.8% MP vs. 35.7% placebo, \( p = 0.02 \) | Improvement in MV-free days: 16.5 ± 10.1 MP vs. 8.7 ± 10.2 days placebo, \( p = 0.001 \) MODS score at 7 days: 0.90 ± 1.1 MP vs. 1.9 ± 1.4 placebo, \( p = 0.002 \) ICU LOS: 7 (6–12) MP vs. 14.5 (7–20.5) days placebo, \( p = 0.007 \) P:F 256 ± 19 MP vs. 179 ± 21 placebo, \( p = 0.006 \) ICU mortality: 20.6% MP vs. 42.9% placebo, \( p = 0.03 \) |
| 7–28 days after ARDS onset | MP IV loading dose of 2 mg/kg then 0.5 mg/kg q6h for 14 days, 0.5 mg/kg q 12h, for 7 days, followed by taper over 2–4 days Duration: 23–25 days | 60-day mortality: 29.2% MP vs. 28.6% placebo, \( p = 1.0 \) | Improvement in MV-free days at 28 days: 11.2 ± 9.4 vs. 6.8±8.5 days placebo, \( p < 0.001 \) No. of ICU-free days at day 28: 8.9 ± 8.2 MP vs. 6.2 ± 7.8 days placebo, \( p = 0.02 \) Organ failure-free days at day 28: 20.7 ± 8.9 vs. 17.9 ± 10.2 days placebo, \( p < 0.0001 \) |
| Unclear | HCT 200 mg IV followed by infusion at 10mg/h Duration: 7 days | P:F > 300 at day 8: 70% HCT vs. 22% placebo, \( p = 0.003 \) P:F ≥ 100 increase from study entry at day 8: 87% HCT vs. 35% placebo, \( p = 0.0007 \) MODS score at day 8: 0.3 ± 0.5 HCT vs. 1.0 ± 0.9 placebo, \( p = 0.003 \) | MV-free days at day 8: 4 (0–7) HCT vs. 0 (0–6) placebo, \( p = 0.01 \) 60-day mortality: 0% HCT vs. 38% placebo, \( p = 0.001 \) |
| Within 8 hrs of the onset of shock | HCT 50 mg IV every 6 hrs + fludrocortisone 50 mcg orally daily or placebo Duration: 7 days | 28-day survival in non-responders: 33/62 (53%) steroid vs. 50/67 (75%) placebo, \( p = 0.013 \) | ICU mortality in non-responders: RR 0.73 (0.57–0.94), \( p = 0.010 \) Days alive and free of MV HCT group of non-responders: 5.7±8.6 steroids vs. 2.6±6.6 placebo, \( p = 0.006 \) 28-day survival in non-responders: RR 0.71 (0.54–0.94), \( p = 0.011 \) Hospital mortality in non-responders: RR 0.75 (0.59–0.96), \( p = 0.016 \) |

(Continued)
glucocorticoids have broad effects to mitigate the pathogenesis of ARDS (Figure 1). Anti-inflammatory properties of glucocorticoids with the potential for glucocorticoid-resistant states in the setting of severe systemic inflammation are proposed to dampen the deranged inflammatory response and prevent progression to the fibroproliferative phase of ARDS. Increased GC-GR binding for patients with non-COVID-19 or COVID-19 ARDS pathophysiology through the above mechanisms may shorten the time for disease resolution and improve outcomes.14

1.2 | Selection of corticosteroids

Given the physiologic benefits derived from glucocorticoid activity, corticosteroids with glucocorticoid effects are preferred in ARDS.15,16 Methylprednisolone, a potent glucocorticoid, leads to increased concentrations in the lung compared to other corticosteroids due to its larger volume of distribution and tendency to be retained in the lungs for a longer period.17-19 When used for ARDS, guidelines suggest weaning methylprednisolone over days to weeks because a rebound increase in pro-inflammatory cytokines may precipitate the recurrence of cytokine storm.19 Recent clinical trials comparing dexamethasone to methylprednisolone in COVID-19 patients suggest greater benefit with methylprednisolone in terms of recovery time/length of hospital stay, intensive care need, and mechanical ventilation.20-22 Of note, these trials used relatively higher doses of methylprednisolone compared to dexamethasone making it unclear if benefit is due to higher dose or corticosteroid selected. Dexamethasone, also a potent glucocorticoid, has a biological half-life up to 54 h allowing concentrations to auto-taper, decreasing the potential for a rebound effect upon discontinuation and need for a prolonged taper when treating ARDS.23,24 Corticosteroids with more potent mineralocorticoid effects, such as hydrocortisone, increase the expression of epithelial sodium channels and activate the basolateral Na+/K+ ATPase pump in the distal portion of the nephron. This promotes sodium reabsorption and increases effective circulating volume, which may lead to pulmonary edema, worsening lung function, and increased duration of mechanical ventilation (MV).25,26

2 | METHODS

A systematic review was completed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines.27 The investigators used OVID MEDLINE and EMBASE databases to identify relevant prospective, randomized control trials (RCTs) conducted in humans ≥18 years old published in English from 1987 up to August 19, 2021. Search terms included: acute respiratory distress syndrome or adult respiratory distress syndrome or COVID-19 and dexamethasone or methylprednisolone or hydrocortisone or glucocorticoid or corticosteroid. Titles and abstracts identified in the literature search were reviewed, with further screening of inclusion criteria, and then retrieval of full-text articles for review. Studies meeting the following PICO (population, intervention, comparator, and outcome) qualities were included: P—adults with COVID or non-COVID-19 ARDS; I—receiving systemic glucocorticoids; C—placebo, standard of care, or other steroid; and O—mortality. Assessment of bias was completed using the Risk of Bias (RoB) 2.0 tool for RCTs.28 Studies were assessed for bias by two investigators for domains including bias from: the randomization process, deviations from the intended interventions, missing outcome data, risk of bias in measurement of the outcome, and risk of bias in selection of the reported result.

### TABLE 1 (Continued)

| Trial | Study Period | Design | Patient Population |
|-------|--------------|--------|--------------------|
| Tongyoo et al, Crit Care 201626 | Dec. 2010-Dec. 2014 | Prospective placebo-controlled parallel-group RCT, DB, Single-center<br>N = 197 | Severe sepsis or septic shock receiving MV meeting AECC criteria for ARDS |
| DEXA-ARDS Lancet Respir Med 202028 | Mar. 2013-Dec. 2018 | Prospective standard care controlled RCT, open label, Multicenter (17 centers) | Moderate-to-severe ARDS based on AECC/Berlin criteria (P:F < 200) on FiO2 ≥ 0.5 and PEEP ≥10 cm H2O |

Abbreviations: AECC, American European Consensus Conference; AEs, adverse events; ARDS, acute respiratory distress syndrome; bpm, breaths per minute; DB, double blind; DEX, dexamethasone; FiO2, fraction of inspiratory oxygen; HCT, hydrocortisone; hrs, hours; IV, intravenously; LIS, lung injury score; MODS, multiorgan dysfunction syndrome; MP, methylprednisolone; MV, mechanical ventilation; NS, non-significant; P, F, partial pressure of oxygen/fraction of inspired oxygen, partial pressure of arterial oxygen; PAWP, pulmonary artery wedge pressure; RCT, randomized controlled trial; RR, relative risk; SD, standard deviation.
3 | RESULTS

A total of 360 articles were identified via database search after removing duplicates (Figure 3). Full text of 25 articles were reviewed and 15 met inclusion criteria including 8877 patients. Data evaluated in these articles are in Tables 1 and 2. RoB assessment was completed for all studies with 8 (53.3%) assessed to have low risk, 6 (40%) with some concerns, and 1 (6.7%) with high risk of bias (Table 3). All included studies were RCTs, with one being a post hoc analysis of an RCT. Of these, 11 (73.3%) studies were multicentered and 4 (2.7%) single-centered. There were 10 (66.7%) double-blinded trials and 5 (33.3%) unblinded. Comparing regimens, 5 (33.3%) studied methylprednisolone, 4 (26.7%) hydrocortisone, 1 (6.7%) hydrocortisone and fluocortisone, 4 (26.7%) dexamethasone, and 1 (6.7%) methylprednisolone compared to dexamethasone. Dosing regimens varied between methylprednisolone studies and between hydrocortisone studies. Dexamethasone was dosed as 20 mg daily for 5 days followed by 10 mg daily for 5 days in 3/5 studies, 2 studies incorporated 6 mg daily for 10 days. All studies reported mortality as a primary or secondary outcome, with 6 (40%) reporting 28-day mortality. Adverse effects are reported in Table 4.

3.1 | Corticosteroids for non-COVID-19-related ARDS

Standard of care for ARDS and management of MV have changed drastically across the time continuum of corticosteroid trials, influencing baseline mortality rates, and efficacy of co-interventions. Outcomes studied have changed from Lung Injury Score (LIS) to difference in $\text{PaO}_2/\text{FiO}_2$ and MV-free days (Table 1). Controversy has continued in the role of corticosteroids in improving clinically meaningful outcomes like mortality, potentially due to overall sample sizes, differences in ARDS definitions, timing of corticosteroid initiation, dosing, and duration, and treatment crossover.

3.2 | Bernard et al. N Engl J Med 1987

Bernard and colleagues studied the effects of high-dose methylprednisolone (30 mg/kg intravenously (IV) every 6 h for 24 h) on mortality in ARDS to understand the effect of corticosteroids on chest radiograph, oxygenation, and lung compliance.29 Notably, there was no difference in the rate of mortality between the corticosteroid [60%; (95% CI, 46–74%)] and placebo groups [63%; (95% CI, 49–77%)], with no difference during 45-day follow-up. In the subgroup analysis of patients with ARDS secondary to sepsis, patients treated with methylprednisolone had a lower reversal of chest radiograph and arterial blood gases vs. placebo (9% vs. 56%, $p < 0.018$) but no difference in survival. Contemporary ventilation practices recommend that patients with ARDS receive lung protective ventilation strategies; however, it is unlikely that such strategies were employed in this study. Criteria for reversal of blood gas were not fully elucidated, so we are unable to apply this finding to clinical practice. Furthermore, the study did not specify the duration, and frequency chest radiographs were evaluated for resolution of bilateral pulmonary edema.

3.3 | Meduri et al. JAMA 1998

In 1998, Meduri and colleagues looked at the effect of prolonged IV methylprednisolone therapy (2 mg/kg/day days 1–14, 1 mg/kg/day days 15–21, 0.5 mg/kg/day days 22–28, 0.25 mg/kg/day days 29–30,
and 0.125 mg/kg/day days 31–32) in late (≥7 days of MV with LIS ≥2.5 and <1 point reduction from ARDS day 1) ARDS on improvement in lung function and mortality. Methylprednisolone therapy was associated with improvement in ARDS defined as >1-point reduction in LIS (1.7 vs. 3; \( p < 0.001 \)) and also led to more ICU survivors (16/16 vs. 3/8 survivors; \( p = 0.002 \)) and survivors of hospital admission (14/16 vs. 3/8; \( p = 0.03 \)). The trial was stopped early and included a small sample size (\( n = 24 \)). There were numerical differences in severity of illness at baseline between treatment and placebo groups. The study protocol allowed for crossover to the other treatment arm in patients who did not have a 1-point reduction in LIS by study day 10. Four patients in the placebo group crossed over to methylprednisolone but 0 patients in the methylprednisolone group crossed over.

### 3.4 | Confalonieri et al. Am J Respir Crit Care Med 2005

This RCT evaluated the effects of hydrocortisone (200 mg loading dose IV followed by a 7-day infusion at 10 mg/h) on improvement in \( \text{PaO}_2/\text{FiO}_2 \) MODS score by study day 8, and reduction in septic shock. While this study did not evaluate ARDS patients specifically, it assessed patients with severe community-acquired pneumonia with a high predisposition to systemic inflammation. This study, suspended after interim analysis of 46 patients, identified a greater improvement in \( \text{PaO}_2/\text{FiO}_2 \) at day 8 as well as hospital mortality (30% vs. 0%). While this study is encouraging, it is limited by a small sample size, including only three patients with ARDS at day 8 in the placebo group and had unbalanced groups at randomization.

### 3.5 | Meduri et al. Chest 2007

Since systemic inflammatory response is established early in the ARDS course, Meduri and colleagues investigated prolonged administration of low-dose methylprednisolone (1 mg/kg/day IV days 1–14, 0.5 mg/kg/day IV days 15–21, 0.25 mg/kg/day IV days 22–25, and 0.125 mg/kg/day days 26–28) in early ARDS (>72 h of diagnosis) with a primary outcome of LIS at day 7. By day 7, 44/63 (69.8%) patients receiving methylprednisolone attained a 1-point reduction in LIS compared with 10/28 (35.7%) in the placebo group (\( p = 0.002 \)).

| Table 1: Mortality and ICU length of stay (LOS) | Reduced in the methylprednisolone group | 20.6% vs. 42.6%; 0.03 and 7 vs. 14.5 days; 0.007, respectively | but hospital mortality and LOS failed to reach statistical significance (23.8% vs. 42.9%; 0.07 and 13 vs. 20.5 days; 0.09, respectively). Despite the positive results, important limitations include the small sample size and the higher incidence of catecholamine-dependent shock in the placebo group which likely contributed to increased mortality. Furthermore, crossover design obscured the analysis as 10 patients in the placebo and 5 in the methylprednisolone group received high-dose methylprednisolone 2 mg/kg/day.

### 3.6 | ARDS Clinical Trials Network. N Engl J Med 2006

As early data demonstrating corticosteroid benefit were mixed using heterogeneous regimens, the ARDSNET trial attempted to better delineate the role of corticosteroids in ARDS on their primary outcome of 60-day mortality. Patients were enrolled 7–28 days after the onset of ARDS and randomized to placebo or 3 weeks of IV methylprednisolone (2 mg/kg followed by 0.5 mg/kg q6h for 14 days followed by 0.5 mg/kg q12h for 7 days followed by taper over 2–4 days if 21 days of corticosteroids completed). The primary outcome of 60-day mortality was not different between placebo and corticosteroid arms (28.6% vs. 29.2%; \( p = 1.0 \)). Patients treated with corticosteroids had a greater incidence of serious adverse events associated with myopathy/neuropathy (9% vs. 0%, \( p = 0.001 \)). Those randomized after 13 days of ARDS onset had increased mortality (8% vs. 35%, \( p = 0.02 \)). Relative to other studies, this trial employed short taper schedules ranging from 2 to 4 days. Subsequent analyses have suggested a positive interaction with prolonged tapering and MV-free days. The treatment group included more females, and a small percentage of total eligible patients were enrolled, bringing into question the generalizability of these results.

### 3.7 | Annane et al. Crit Care Med 2006

Annane and colleagues completed a post hoc analysis of their trial using hydrocortisone 50 mg IV every 6 h and enteral hydrocortisone 50 μg daily in patients with septic shock and relative adrenal insufficiency to assess the primary outcome of 28-day mortality. Fifty-nine percent of the study population had mild ARDS (mean \( \text{PaO}_2/\text{FiO}_2 \) 270 mmHg) on inclusion. In post-hoc analysis of non-responders (cortisol response ≤9 μg/dl) with ARDS, 28-day mortality was 50/67 (75%) in the placebo group and 33/62 (53%) in the corticosteroid group (adjusted RR 0.71 [0.54–0.94, \( p = 0.011 \)]. Hospital and ICU mortality were lower in the corticosteroid group compared to placebo (adjusted OR 0.38: 95% CI 0.16–0.88 and adjusted OR 0.35: 95% CI 0.15–0.82, respectively). In responders (cortisol response >9 μg/dl from baseline) with ARDS and patients without ARDS, there was no difference in mortality, and days alive and MV-free. The mean tidal volume in all patients with ARDS was >8 ml/kg, indicating not all patients received lung protective ventilation. The results of this study may not be generalizable to ARDS patients without septic shock.

### 3.8 | Tongyoo et al. Crit Care 2016

Sepsis-associated ARDS confers higher mortality rate compared to sepsis without ARDS or in non-sepsis-related ARDS. Tongyoo and colleagues conducted a prospective RCT studying hydrocortisone 50 mg IV every 6 h for 7 days on 28-day mortality. There was no difference in 28-day mortality, 22/98 (22.5%) vs. 27/99 (27.3%);
During initial stages of the COVID-19 pandemic, corticosteroids were not recommended for use due to previous evidence from the SARS and MERS outbreaks suggesting delayed viral clearance and worse outcomes. Patients with COVID-19 often progress to systemic inflammatory response syndrome, furthering lung injury and damaging multiple organ systems which similarly to non-COVID-19 ARDS may be attenuated by anti-inflammatory properties of corticosteroids.

Heterogeneous steroid regimens were studied among COVID-19 patients with a wide range of illness severity (Table 2).
| Trial                                      | Study period | Design | Patients                                                                 | Background therapy                                                                 | % MV or ARDS at baseline                      |
|-------------------------------------------|--------------|--------|--------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-----------------------------------------------|
| RECOVERY N Engl J Med 2020⁴²              | Mar.-Jun. 2020 | RCT    | Hospitalized adult patients with clinically suspected or laboratory-confirmed SARS-CoV-2 infection | REM = 3 patients<br>Anti-IL6: 0–3%<br>Azithromycin –25% both arms<br>CP: 0%         | %MV:<br>1007/6425 (16%)<br>DEX: 324/2104 (15%)<br>Placebo: 683/4321 (16%)<br>P:F not reported |
| REMAP-CAP JAMA 2020⁴³                     | Mar.-Jun. 2020 | RCT    | Adults with severe COVID-19 69–81% confirmed infection                   | Co-enrolled with antibiotic arm, anti-viral arm, details unavailable<br>CP: 0%<br>Anti-IL6: 0% | % MV:<br>Fixed dose: 87/137 (63.5%)<br>Shock dependent: 73/146 (50%)<br>No HCT: 53/ 101 (52.5%)<br>Baseline P:F 141 |
| CAPE-COVID JAMA 2020⁴⁴                   | Mar.- Jun. 2020 | RCT    | Adult ICU patients with respiratory failure secondary to COVID-19        | >40% both groups received hydroxychloroquine and azithromycin<br>Anti-IL6: –2% both groups<br>CP: 0%<br>REM: –3% both groups | % MV:<br>HCT: 81.6%<br>Placebo: 80.8%<br>Mean P:F<br>HCT: 130<br>Placebo: 133 |
| CoDEX JAMA 2020⁴⁵                        | Apr.-Jun. 2020 | RCT    | Adult MV patients within 48 hrs of meeting criteria for moderate-to-severe ARDS | REM not available<br>-20% both arms HCQ<br>-65% both arms Azithromycin<br>0% anti-IL<br>0% CV<br>0% REM | %MV: 100%<br>Moderate-to-severe ARDS          |
| Metcovid Clin Infect Dis 2020⁴⁶           | Apr.-Jun. 2020 | RCT    | Hospitalized adults with suspected COVID-19* with SpO₂ ≤ 94%, or requiring supplementary oxygen or MV 81.3% confirmed by SARS-CoV-2 PCR | 0% REM<br>0% anti-IL6 0% CP<br>HC for shock MP vs. placebo: 8.7% vs. 7.0% | %MV: 33.8%<br>MP: 53/66 (80.3%)<br>Placebo: 57/67 (85.1%)<br>% non-invasive O₂: 188/393 (47.8%)<br>Median P:F 158<br>MP: 160<br>Placebo: 156 |
| Jamaati et al. Eur J Pharmacol 2021⁴⁷     | Mar. 2020     | RCT    | Laboratory-confirmed SARS-CoV-2 infection Mild-to-moderate ARDS (P:F 100–300 mmHg) Excluded: CKD, chronic liver disease, and hyperglycemic | 100% lopinavir/ritonavir 400/100 mg BID<br>REM not reported<br>Anti-IL6 not reported | %MV: not reported<br>100% ARDS                 |
| Ranjar et al. BMJ Inf Dis 2021²⁰          | Aug.–Nov. 2020 | RCT    | Hospitalized adults with confirmed COVID-19 with SpO₂ ≤ 92%              | Standard of care, specific therapies not listed                                   | Not reported                                  |

Abbreviations: anti-IL, interleukin inhibitor; CKD, chronic kidney disease; CP, convalescent plasma; CT, computed tomography; DEX, dexamethasone; HCQ, hydroxychloroquine; HCT, hydrocortisone; ICU, intensive care unit; IV, intravenous; MP, methylprednisolone; MV, mechanical ventilation; P:F, partial pressure of oxygen/fraction of inspired oxygen; PCR, polymerase chain reaction; RCT, randomized controlled trial; REM, remdesivir; SpO₂, oxygen saturation.
| Timing of Initiation | Drug Dose/route/frequency | Total duration (days) | Mortality | Organ failure-free days | Other Outcomes |
|---------------------|---------------------------|-----------------------|-----------|------------------------|----------------|
| 8 days (DEX arm) vs. 9 days (usual care arm) | DEX 6 mg IV daily 10 or until hospital discharge | 28-d mortality 22.9% DEX vs. 25.7% placebo \( p < 0.001 \) | Not reported | Time until hospital discharge Progression to MV RR, 0.79 (95% CI, 0.64–0.97) Removal of invasive MV in those receiving MV at randomization: RR, 1.47 (95% CI 1.20–1.78) |
| 13.5 hrs from ICU admission | HCT IV 100 every 6 hours HCT IV 50 every 6 hours | 28-d mortality fixed-dose 30%, shock dependent 26%, and placebo 33%, \( p = \text{NS} \) | Median organ support failure-free days 0 in all three groups, \( p = \text{NS} \) | Fixed-dose HCT reduced days free of vasopressor/inotropes: OR 1.68 (1.03, 2.59) Fixed-dose HCT reduced progression to intubation, ECMO, or death of those not on MV or ECMO at baseline OR 3.02 (1.18, 6.56) |
| Majority >1 week; Not all patients had MV | HCT continuous infusion 200 mg x 7days, 100 mg x 4 days, and 50 mg x 3 days | All-cause mortality at 21 days 14.7% HCT vs. 27.4% placebo, \( p = 0.06 \) | Not reported | Treatment failure at day 21 (death or persistent dependency on MV or high-flow oxygen therapy) 42.1% HCT vs. 50.7% placebo |
| 9 days (DEX arm) vs. 10 days (standard-of-care arm); 1 day for both arms | DEX 20 mg IV daily x 5 days, and then 10 mg IV daily x5 days | All-cause mortality at 28 days 56.3% DEX vs. 61.5% placebo, \( p = 0.85 \) | Ventilator-free days 6.6 DEX vs. 4 placebo \( p = 0.04 \) | 6-point ordinal scale at day 15.5 (3–6) DEX vs. 5 (5–6) placebo, \( p = 0.07 \) ICU-free days at 28 days 2.1 DEX vs. 2.0 placebo, \( p = 0.5 \); Mean SOFA score at 7 days 6.1 DEX vs. 7.5 placebo, \( p = 0.004 \) |
| Median 3 days from MV, 13 days from illness onset to randomization | MP IV 0.5 mg/kg twice daily | 28-day mortality MP 37.1% vs. 38.2% placebo, \( p = 0.629 \) | Not reported | No difference in any outcomes between MP and placebo Need for intubation (19.4% vs. 16.8%, \( p = 0.654 \)) Length of hospitalization (10 days vs. 9 days, \( p = 0.296 \)) |
| Presumably upon hospital presentation, median presentation of symptom onset to admission = 8 days | DEX 20 mg IV daily x 5 days, then 10 mg IV daily x 5 days | 28-day mortality: 64% DEX vs. 60% control, \( p = 0.500 \) | Not reported | Need for invasive MV: 52% DEX vs. 44% control, \( p = 0.389 \) Weaning from \( Q_s \) support: Hospital LOS: 11 days (6–16) DEX vs. 6 (4–9), \( p = 0.036 \) Improvements in CT: 40% DEX vs. 12% control |
| Not reported | MP IV 2 mg/kg/day tapered by 50% every 5 days vs. DEX 6mg IV daily | 28-day mortality MP 18.6% vs. 37.5% DEX, \( p = 0.07 \) WHO ordinal scale at days 0, 5, and 10 improved in MP group, \( p = 0.001 \) | Hospital LOS 7.43 ± 3.64 days MP vs. 10.52 ± 5.47DEX MP reduced need for MV 18.2% vs. DEX 38.1%, \( p = 0.04 \) |
| Trial                                                                 | Domain 1: Risk of bias arising from randomization process | Domain 2: Risk of bias due to deviations from the intended interventions (effect of assignment to intervention) | Domain 3: Missing outcome data | Domain 4: Risk of bias in measurement of the outcome | Domain 5: Risk of bias in selection of the reported result | Overall Risk of Bias |
|----------------------------------------------------------------------|----------------------------------------------------------|---------------------------------------------------------------------------------|-------------------------------|-----------------------------------------------|----------------------------------------------------------|---------------------|
| Non-COVID-19 ARDS Studies                                            |                                                          |                                                                                 |                               |                                               |                                                          |                     |
| Bernard et al. *N Engl J Med* 1987<sup>29</sup>                      | Low                                                      | Low                                                                             | Low                           | Low                                           | Low                                                      | Low                 |
| Meduri et al. *JAMA* 1998<sup>30</sup>                               | Low                                                      | Low                                                                             | Low                           | Low                                           | Low                                                      | Low                 |
| Meduri et al. *CHEST* 2007<sup>32</sup>                              | Low                                                      | Low                                                                             | Low                           | Low                                           | Low                                                      | Low                 |
| ARDS Clinical Trials Network. *N Engl J Med* 2006<sup>16</sup>        | Low                                                      | Low                                                                             | Low                           | Low                                           | Low                                                      | Low                 |
| Confalonieri et al. *Am J Respir Crit Care Med* 2005<sup>31</sup>     | Low                                                      | Some Concerns<sup>a</sup>                                                      | Low                           | Low                                           | Low                                                      | Some Concerns       |
| Annane et al. *Crit Care Med* 2006<sup>35</sup>                      | Low                                                      | Low                                                                             | Low                           | Low                                           | Some Concerns<sup>b</sup>  | Some Concerns       |
| Tongyoo et al. *Crit Care* 2016<sup>36</sup>                         | Low                                                      | Low                                                                             | Low                           | Low                                           | Low                                                      | Low                 |
| DEXA-ARDS *Lancet Respir Med* 2020<sup>38</sup>                       | Low                                                      | Low                                                                             | Low                           | Low                                           | Some Concerns<sup>e</sup>  | Some Concerns       |
| COVID-19 ARDS Studies                                                |                                                          |                                                                                 |                               |                                               |                                                          |                     |
| RECOVERY *N Engl J Med* 2020<sup>42</sup>                             | Low                                                      | Low                                                                             | Low                           | Low                                           | Low                                                      | Low                 |
| REMAP-CAP *JAMA* 2020<sup>43</sup>                                    | Low                                                      | Some Concerns<sup>a</sup>                                                      | Low                           | Low                                           | Low                                                      | Some Concerns       |
| CAPE-COVID *JAMA* 2020<sup>44</sup>                                  | Low                                                      | Low                                                                             | Low                           | Low                                           | Some Concerns<sup>c</sup>  | Some Concerns       |
| CoDEX *JAMA* 2020<sup>45</sup>                                       | Low                                                      | Low                                                                             | Low                           | Low                                           | Low                                                      | Low                 |
| Metcovid *Clin Infect Dis* 2020<sup>46</sup>                         | Low                                                      | Low                                                                             | Low                           | Low                                           | Low                                                      | Low                 |
| Jamaat et al. 47<sup>47</sup>                                        | Low                                                      | Some Concerns<sup>f</sup>                                                      | Low                           | Low                                           | Low                                                      | Some Concerns       |
| Ranjbar et al. *BMJ Inf Dise* 2020<sup>40</sup>                      | Low                                                      | Some Concerns<sup>a</sup>                                                      | Low                           | Low                                           | Low                                                      | Some Concerns       |

<sup>a</sup>Some concerns: due to analysis excluding patients who exited the study, etc., and not intention-to-treat analysis.

<sup>b</sup>Some concerns: this was a post hoc analysis of an RCT due to the nature of not being pre-planned has some concerns for bias risk.

<sup>c</sup>Some concerns: mortality at day 21 was a post hoc outcome.

<sup>d</sup>Possible that missingness in outcome influenced by true value in patients who exited study due to adverse effects/ no information.

<sup>e</sup>Domain 5 assessed as some concerns as a result of trial being stopped prior to enough patients being enrolled to meet power; data were not analyzed in accordance with pre-specified analysis plan (domain 5.1). There were no multiple eligible outcome measurements (5.2) or analyses of the data (5.3).

<sup>f</sup>Unclear if analysis was intent to treat.
data were available for 99% of patients. There were 10 safety events reported in the corticosteroid arms, and one in the control arm; however, details were not reported, and secondary infection rates are likely underreported (Table 4). This trial was halted early following release of RECOVERY findings. Limitations of this study include the unblinded treatment arms and up to 15% of the no-HCT group received a corticosteroid. Strengths include an intent-to-treat analysis of outcomes, including a primary analysis of corticosteroid-only patients.

3.13 | CAPE-COVID JAMA 2020

The effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19 (CAPE-COVID) evaluated the effect of hydrocortisone (200 mg/day IV until day 7, 100 mg/day IV days 8-11, and then 50 mg/day IV days 12-14) in ICU patients with COVID-19 acute respiratory failure.44 The primary outcome was treatment failure (death or persistent dependency on MV or high-flow oxygen therapy) at day 21 from randomization. Treatment failure occurred in 32/76 (42.1%) vs. 37/73 (50.7%) of those in the hydrocortisone group vs. the placebo group, respectively; difference of proportions, −8.6% [95.48% CI, −24.9% to 7.7%]; p = 0.29. Mortality rates were not statistically different between groups. At day 28, 58 patients had at least one nosocomial infection. This study was terminated early after publication of the RECOVERY trial and was underpowered for the primary outcome. Other limitations include >40% of patients enrolled in each group were receiving alternative experimental drugs for the treatment of COVID-19 (i.e., hydroxychloroquine and azithromycin). The trial is not generalizable as severity criteria for enrollment was based on respiratory function and the time to administration of treatment, and not representative of a pure ARDS population.

3.14 | CoDEX JAMA 2020

The COVID-19-associated ARDS treated with DEXamethasone (CoDEX) trial randomized patients to dexamethasone (20 mg IV daily days 2-5, 10 mg IV daily days 6-10, or until ICU discharge) or standard of care and assessed the primary outcome of MV-free days at 28 days.45 Patients randomized to the dexamethasone group had a mean 6.6 MV-free days (95% CI, 5.0–8.2) during the first 28 days vs. 4.0 MV-free days (95% CI, 2.9–5.4) in the standard care group (difference, 2.26; 95% CI, 0.2–4.38; p = 0.04). There was no significant difference in the prespecified secondary outcomes of all-cause mortality at 28 days, ICU-free days during the first 28 days, MV duration at 28 days, or the 6-point ordinal scale at 15 days. While all patients had moderate-to-severe ARDS in this trial, a limitation is the low proning rate of 22%. Strengths of the trial include the multicenter design, and collection of detailed adverse effects and physiologic data.

3.15 | Metcovid Clin Infect Dis 2020

The Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid) was a double-blind, randomized trial of hospitalized adult patients with suspected COVID-19 and randomized patients to methylprednisolone 0.5 mg/kg IV twice daily for 5 days to assess the primary outcome of 28-day mortality.46 There was no difference in 28-day mortality between methylprednisolone and placebo (37.1% vs. 38.2%, p = 0.629), need for intubation (19.4% vs. 16.8%, p = 0.654), or hospital LOS (10 days vs. 9 days, p = 0.296). Additionally, there was no difference in the need for insulin therapy, positive blood cultures, or sepsis. In a post hoc subgroup analysis of MV patients, there was no difference in 28-day mortality between methylprednisolone and placebo (80.3% vs. 85.1%, p = 0.266). In a post hoc subgroup analysis of patients >60 years old, 28-day mortality was lower in the methylprednisolone group (46.6% vs. 61.9%, p = 0.039). These patients also had higher median C-reactive protein values than those <60 years old (81.3 mg/L vs. 74.7 mg/L, p = 0.0028). Limitations of this trial include the single-center design, and delayed corticosteroid administration (3 days from MV and 13 days from illness onset). Additionally, the study included patients who may not have had COVID-19 (only 81.3% confirmed with SARS-CoV-2 polymerase chain reaction) with no separate outcome analysis on the confirmed COVID-19 cohort. Importantly, the primary outcome was not limited to a MV/ARDS population (analyses in MV were post hoc), and only 36.2% required ICU admission. Overall, there were no differences in the incidence of bacteremia/sepsis; however, all patients received antibiotics (ceftriaxone + macrolide).

3.16 | Jamaati et al. Eur J Pharmacol 2021

In their unblinded RCT, Jamaati and colleagues randomized 50 patients to receive dexamethasone 20 mg for 5 days, followed by 10 mg for 5 days vs. the control group in patients with mild-to-moderate ARDS.47 Patients presented to the hospital a median of 8 days after symptom onset with randomization presumably on admission. The primary outcomes of invasive ventilation and 28-day mortality rate were studied with no difference in 28-day mortality (64% dexamethasone vs. 60% control, p = 0.500). MV was needed in 13 (52%) of the dexamethasone group and 11 (44%) of the control, p = 0.389. Patients with chronic kidney disease, chronic liver disease, and those presenting with hyperglycemia were excluded in addition to its small sample size, limiting the generalizability of these findings. Additionally, it is unknown what effect other therapies (lopinavir/ritonavir 400/100 mg twice daily) may have had with no other studies included in our review using this concomitant therapy.

3.17 | Ranjbar et al. BMC Infect Dis 2021

A recent triple-blinded RCT compared methylprednisolone vs. dexamethasone for COVID-19.20 Eighty-six patients were randomized 1:1 to 10 days of tapering methylprednisolone 2mg/
| Trial | ICU-AW | Hyperglycemia | Infection | Other |
|-------|--------|---------------|-----------|-------|
| **ARDS Studies** | | | | |
| Bernard et al. *N Engl J Med* 1987 | Not reported | Higher glucose in MP vs. placebo, \( p < 0.01 \) | Similar incidence: 16% MP vs. 10% placebo, \( p = 0.60 \) | No idiosyncratic reactions and no differences in blood hemoglobin levels |
| Meduri et al. *JAMA* 1998 | Not reported | Similar incidence: 16% MP vs. 10% placebo, \( p = 0.60 \) | Similar rate of new infection: 75% MP vs. 50% placebo | Reduction of hemoglobin >0.20: 6% MP vs. 50% placebo, \( p = 0.03 \) |
| Meduri et al. *CHEST* 2007 | Similar neuromuscular weakness: 6.4% MP vs. 3.6% placebo, \( p = 1.0 \) | Similar hyperglycemia requiring insulin: 71.4% MP vs. 64.3%, \( p = 0.50 \) | Lower rate of new infection: 40/63 MP vs. 40/28 placebo, \( p = 0.0002 \) | Pneumothorax: 7.9% MP vs. 21.4% placebo, \( p = 0.09 \) |
| **ARDS Clinical Trials Network, *N Engl J Med* 2006** | Increased serious AEs associated with myopathy or neuropathy: 9 MP vs. 0 placebo, \( p = 0.001 \) | Mean serum glucose level higher days 1, 2, and 4 in MP vs. placebo | Similar no. of serious infections/no. of patients: 25/20 MP vs. 43/30 placebo, \( p = 0.14 \) | Not reported |
| Confalonieri et al. *Am J Respir Crit Care Med* 2005 | Similar polyneuropathy of critical illness: 0% HCT vs. 13% placebo, \( p = 0.23 \) | Not reported | Similar nosocomial infection 0% HCT vs. 18% placebo, \( p = 0.11 \) | Delayed septic shock: 0% HCT vs. 52% placebo, \( p < 0.001 \) |
| Annane et al. *Crit Care Med* 2006 | Not reported | Not reported | No difference in superinfection between responder and non-responder groups in steroids vs. placebo groups | No difference in GI bleeding between responder and non-responder groups in steroid vs. placebo groups |
| Tongyoo et al. *Crit Care* 2016 | Not reported | Higher rate of hyperglycemia: 80.6% HCT vs. 67.7% placebo, \( p = 0.04 \) | Similar rates of nosocomial infection: 17.3% HCT vs. 19.2% placebo, \( p = 0.74 \) | No difference in psychiatric effects between responder and non-responder groups in steroid vs. placebo groups |
| **DEXA-ARDS *Lancet Respir Med* 2020** | Not reported | No difference in hyperglycemia in the ICU: \( p = 0.33 \) | No difference in new infection in the ICU: \( p = 0.75 \) | No difference in barotrauma |
| **COVID-19 Studies** | | | | |
| RECOVERY *N Engl J Med* 2020 | Not reported | 2 patients with hyperglycemia | Not reported | 1 patient with GI bleed 1 patient with psychosis |
| REMAP-CAP *JAMA* 2020 | 1 patient with severe neuromyopathy in fixed HCT group, investigators thought possibly related to study group assignment | Not reported | 1 patient with fungemia in fixed HCT group, investigators thought possibly related to study group assignment | No significant difference in serious AEs in steroid arms (4 fixed dose and 5 shock dependent) vs. 1 in control |

(Continues)
LANDOLF et al.

kg/day or dexamethasone 6 mg daily to assess the primary outcome of 28-day mortality. Mortality at 28 days was 37.5% in the dexamethasone arm, vs. 18.6% in the methylprednisolone arm, \( p = 0.076 \). The WHO ordinal scale was assessed at baseline, day 5, and day 10, by repeated measures ANOVA and was significantly improved in the methylprednisolone group, \( p = 0.001 \). Hospital LOS among survivors was reduced in the methylprednisolone arm 7.43 ± 3.64 days vs. 10.52 ± 5.47 days in dexamethasone arm, \( p = 0.015 \). It is unclear how many patients in this trial had ARDS, and baseline PaO\(_2\)/FiO\(_2\) was not available. Strengths include the blinded design and dosing strategy of methylprednisolone. The lack of a placebo group limits the overall interpretation of this study, as does the lack of detail regarding the cohorts, including severity of lung dysfunction at baseline, concomitant COVID-19 treatments, and lack of adverse drug event reporting. However, the high baseline mortality rate appears to be similar to other COVID-19 ARDS trials, suggesting this trial treated patients with a high severity of illness.

A common theme among the COVID-19 ARDS studies is a lack of an intent-to-treat analysis on patients with confirmed SARS-CoV-2 infection, and in those who received the study drug, along with open label design. Most of the studies were also stopped prematurely due to the early publication of RECOVERY trial findings, leading to failure to reach statistical power. Many of the trials were conducted during the initial surge of the COVID-19 pandemic and the results may not reflect the risks or benefits within the framework of the current standard of care for these patients. Only one trial compared different corticosteroid regimens, yet this trial is the smallest and has the most profound limitations.

### 3.18 | Adverse effects

As corticosteroids become more widely used for ARDS, consideration for adverse drug events is warranted. Short-term corticosteroid use is associated with hyperglycemia, behavioral disturbances, or cutaneous effects. Long-term corticosteroid use may lead to weight gain, osteoporosis, and ocular and cardiovascular effects. Critically ill patients may have increased risk of developing bacterial or fungal infections or stress-related mucosal damage. In general, corticosteroid regimens should be limited to the lowest dose over the shortest duration to limit these reactions. Here, we describe short-term adverse drug events associated with corticosteroid use in COVID-19 ARDS and report adverse effects from the included studies in Table 4.

#### 3.18.1 | Intensive care unit-acquired weakness

Intensive care unit-acquired weakness (ICU-AW) is new-onset generalized muscle weakness developing during ICU admission presenting in various forms, including critical illness polyneuropathy (CIP) and critical illness myopathy (CIM). ICU-AW may lead to prolonged
MV, prolonged ICU, and hospital LOS, and mortality.51,52 The incidence of ICU-AW is reported to be 40%, with increased incidence in those with MV (65%), ARDS (60%), or sepsis (67%) and remains high at hospital discharge (36%), contributing to long-term disability among survivors.52-55 Corticosteroids are thought to contribute to ICU-AW through the breakdown of myosin and impairment of muscle membrane excitability.53 A systematic review/meta-analysis found corticosteroid use was associated with increased odds of ICU-AW (OR 1.84; 95% CI 1.26–2.67; p = 0.002).56 Those who received corticosteroids had higher overall incidence of ICU-AW compared to the control group (43% vs. 34%); however, these results may have been influenced by concurrent sepsis or use of MV.

Previous studies describing the additive risk for ICU-AW with concomitant use of corticosteroids and NMB must be interpreted with caution. Such studies evaluated corticosteroid doses higher than those used for ARDS in current practice.57 These studies also evaluated amino-nosteroidal NMB rather than benzylisoquinoline NMB for prolonged durations.58 More recent studies evaluating the combined effects of corticosteroids and NMB on ICU-AW have failed to show additive risk.57,59

3.18.3 | Infection

Corticosteroid administration brings forth a double-edged sword of concern in the COVID-19 pandemic. Corticosteroids induce an immunosuppressed state through sequestration of CD4+ T cells and inhibition of cytokine transcription.65 Chronic use has been associated with reduction in natural killer cells and complement pathway activation.66 Additionally, reduced reactive oxygen species production and increased pro-inflammatory cytokine release (e.g., IL-6 and tumor necrosis factor-α) combined with an increase in apoptosis leading to fewer T and B cells may increase the risk of infection.

Among those with COVID-19, the risk of secondary infection from corticosteroid use may be as high as 25% for bacterial and 12.7% for fungal infections.67 A systematic review and meta-analysis with over 6,000 patients found that patients with influenza treated with corticosteroids were more likely to develop secondary bacterial or fungal infections compared to those not receiving steroids (RR 2.0, 95% CI 1.0 to 3.8; p = 0.04).55 The incidence of bacterial co-infection in COVID-19 patients may be as high as 28%, although co-infection and secondary infection are difficult to differentiate.68 Interestingly, the recent COVID-19 corticosteroid trials have not reported a high incidence of secondary infections compared to placebo (Table 4). Of particular concern with corticosteroid use is the potential for fungal or opportunistic infections. Fungal infections in SARS had an incidence of 33% in severe disease and fungal infection-associated mortality in 73.7% of cases.59 The risk for fungal infections should not be minimized, with the rate of presumed invasive pulmonary aspergillosis reported as high as 19.4% among COVID-19 admitted patients.70 One patient in the REMAP study developed fungemia that the authors associated with hydrocortisone; otherwise fungemia was not reported in the other included trials.43 In addition to fungal disease, infection due to strongyloidiasis is also of concern.71,72

3.18.4 | Central nervous system

Central nervous system effects include behavioral, psychiatric, and cognitive effects. Behavioral effects associated with corticosteroid therapy include sleep disturbances and “steroid euphoria.” Sleep disorders (restlessness and insomnia) occur in up to 73% of patients on corticosteroids.6 Approximately 20% of patients treated with corticosteroids develop psychiatric disorders, including depression (40.5%), mania (27.8%), psychosis (13.9%), and delirium (10.1%).7,73 Cognitive effects (difficulty concentrating, memory loss, and delirium) are generally dose and time dependent and remission occurs with drug withdrawal or decreased doses.73 The mechanism leading to this effect is thought to be due to endogenous corticosteroid binding to receptors in the prefrontal cortex, hippocampus, and basolateral amygdala modulating the hunger, sleep–wake cycle, memory, and learning.75 Thus, modifying the release of dopamine and serotonin, and affecting the processing of emotional information and memory.

Patients with COVID-19 can experience memory loss, cognitive decline, anxiety, and depression after recovery from acute illness.76 Corticosteroid use in these patients may further predispose them to these effects. Factors associated with psychosis among patients with SARS include a higher total dose of corticosteroids compared to...
those without (10,975 mg vs. 6,780 mg hydrocortisone equivalent) lending credibility to this concern.77

3.18.5 | Viral shedding

Recognizing potential for already prolonged viral shedding in COVID-19, concerns for further prolongation with corticosteroid use must be considered. Li and colleagues evaluated 206 COVID-19 patients for the proposed dose–response effect of corticosteroid dose on COVID-19 viral shedding finding high-dose (80 mg/day prednisone; aHR, 0.67 [95% CI, 0.46–0.96]; p = 0.031), not low-dose (40 mg/day prednisone; aHR, 0.72 [95% CI, 0.48–1.08]; p = 0.11) corticosteroids associated with delayed viral shedding.60 Whether prolonged viral shedding correlates with a longer duration of symptoms remains unclear.

4 | DISCUSSION

Given the mixed findings from trials evaluating the use of corticosteroids in ARDS, and variability of regimens, the decision of whether, when, and how to initiate corticosteroids for ARDS should be patient specific. Prior to the DEXA-ARDS trial, previous guidelines evaluating the use of corticosteroids in non-COVID-19 ARDS stated the evidence was insufficient while other guidelines recommend corticosteroid use for early management of non-COVID-19-ARDS and warn of potential harm when starting methylprednisolone greater than 14 days from symptom onset.16,19,78 Corticosteroids may have a positive disease-modifying effect and benefits of therapy may outweigh the risk of adverse effects. However, in critically ill patients with COVID-19 ARDS, benefits of corticosteroids have been clearly reported, and therefore use is recommended in this subset of patients.79–81 The studies included in our review found mortality benefit in 6/15 (40%) studies with benefit being seen at varying time points (ICU survival, hospital, and 28 and 60 days) in the COVID-19 and non-COVID-19 studies. One non-COVID-19 ARDS trial found an increased risk of mortality at both 60 and 180 days in patients receiving methylprednisolone greater than 14 days after symptom onset.120 Interestingly, studies showing 28-day mortality benefit in COVID-19 were the largest trial (RECOVERY), and a post hoc analysis of patients >60 years old in the Metcovid trial. These findings align with a meta-analysis finding all-cause mortality benefit with the use of corticosteroids for COVID-19 ARDS.80 The two non-COVID-19 trials assessing LIS improvements found significant improvements with corticosteroid use.30,32 The four non-COVID-19 ARDS trials assessing MV-free days found a significant increase in MV-free days compared to placebo.14,31,32,35 The increase in MV-free days has been previously supported in a meta-analysis of RCTs using corticosteroids for ARDS patients.81 This systematic review included data from RCTs and assessment of bias was completed with the RoB 2.0 tool strengthening our review. Additionally, the majority of included studies were multicenter and many were blinded. Furthermore, we included both COVID-19 and non-COVID-19 ARDS RCTs. A limitation of included studies is heterogeneity in terms of corticosteroid agent, dosing, and duration. Time to initiation of corticosteroids from symptom onset varied, more in the non-COVID-19 ARDS RCTs (4 within 30 h, 3 at >7 days) compared to COVID-19 RCTs, where corticosteroids were often started >7 days after symptom onset. Comparison of specific adverse effects varied between the included RCTs with some trials not including this data, limiting our ability to evaluate this information. Additionally, not all trials reported number of patients with ARDS in addition to there being variations in diagnosis of ARDS. Lastly, therapies received in addition to corticosteroids greatly varied in the COVID-19 ARDS studies, with few patients overall receiving remdesivir, anti-IL6, azithromycin, hydroxychloroquine, lopinavir/ritonavir, or convalescent plasma.

The preferred corticosteroid for ARDS remains to be determined, however, glucocorticoid activity appears to have superior effects on lung inflammation. Data thus far suggest dexamethasone or methylprednisolone be used for the treatment of non-COVID and COVID-19 ARDS. The non-COVID-19 ARDS historical and contemporary data provide the strongest evidence for methylprednisolone and dexamethasone. Mortality data for COVID-19 ARDS are the strongest with the use of dexamethasone in the RECOVERY trial; however, a small RCT found greater benefit with methylprednisolone over dexamethasone.20,42 Perhaps this variability exists because the optimal regimen has not yet been studied in large, prospective, blinded, RCTs. Additionally, enrichment strategies using ARDS subphenotypes should be considered in future trials. Such data may better determine corticosteroid benefit for the right patient, using the right drug, and at right dose.82

5 | CONCLUSION

Corticosteroids have been shown to improve mortality and MV-free days in both COVID-19 and non-COVID-19 ARDS, with evidence suggesting their use in these settings.39,77,80 Vigilant monitoring to promote the safe and effective use of corticosteroid dosing, duration, and drug selection is necessary.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

ORCID

Kaitlin M. Landolf https://orcid.org/0000-0002-4633-3279
Jackie P. Johnston https://orcid.org/0000-0003-0176-1752
Karen Berger https://orcid.org/0000-0003-3686-3468
Mojdeh S. Heavner https://orcid.org/0000-0003-3007-7685
Melissa L. Thompson Bastin https://orcid.org/0000-0001-8047-5978
ARDS outcomes: analysis of individual patients’ data from four randomized trials and trial-level meta-analysis of the updated literature. *Intensive Care Med.* 2016;42(5):829-840. doi:10.1007/s00134-015-4095-4

38. Villar J, Ferrando C, Martinez D, Ambros A, Munos T. Cytokine storm intervention in the early stages of COVID-19 pneumonia. *Cytokine Growth Factor Rev.* 2020;53:38-42. doi:10.1016/j.cytogfr.2020.04.002

39. COVID-19 Treatment Guidelines Panel. *Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.* National Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/. Accessed August 19, 2021.

40. Sun X, Wang T, Cai D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. *Lancet Respir Med.* 2020;8(3):267-276. doi:10.1016/S2213-2600(19)30417-5

41. Dequin P-F, Heming N, Meziani F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. *JAMA.* 2020;324(13):1317-1329. doi:10.1001/jama.2020.17022

42. Horby P, Lim W, Emberson J, et al. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. *N Engl J Med.* 2020;384(8):693-704. doi:10.1056/NEJMoa2021436

43. Angus DC, Derde L, Al-Beidh F, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol.* 2020;146(1):110-118. doi:10.1016/j.jaci.2020.04.006

44. Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on critical illness neuromuscular abnormalities: a historical review. *J Crit Care.* 2019;897:173947. doi:10.1016/j.ejphar.2021.173947

45. Jeronimo C, Farias M, Val F, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): a randomised, double-blind, phase IIIb, Placebo-controlled trial. *Clin Infect Dis.* 2021;72(9):e373-e381. doi:10.1093/cid/ciaa1177

46. JamaatI H, Hashemian SM, Farzanegan B, et al. No clinical benefit of glucocorticoids. *Diabetes.* 2020;69(12):289-294. doi:10.1016/j.diabres.2020.06.006

47. Gensler LS. Glucocorticoids. *Psychiatry Clin Neurosci.* 2009;63(5):613-622. doi:10.1111/j.1440-1819.2009.02005.x

48. Wilcox SR. Corticosteroids and neuromuscular blockers in development of critical illness neuromuscular abnormalities: a historical review. *J Crit Care.* 2017;37:149-155. doi:10.1016/j.jcrc.2016.09.018

49. Alhazzani W, Alshahri M, Jaeschke R, et al. Neuromuscular blocking agents in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials. *Crit Care Lond Engl.* 2013;17(2):R43. doi:10.1186/cc12557

50. Curtis J, Westfall A, Allison J, et al. Population-based assessment of influenza and COVID-19 associated ICU–acquired weakness syndromes: a systematic review and meta-analysis of randomized controlled trials. *Crit Care.* 2020;24(12):e120. doi:10.1186/s13054-018-2111-0

51. Bhattacharya S, Alshahri M, Alhazzani W, et al. Corticosteroids and neuromuscular blockers in severe COVID-19: a systematic review and meta-analysis of randomized controlled trials. *Crit Care.* 2021;25(1):36. doi:10.1186/s13054-021-03550-3

52. Alshahrani M, Alshahri M, Alhazzani W, et al. Corticosteroids and neuromuscular blockers in critical illness: a systematic review. *Respir Care.* 2020;65(10):1362-1371. doi:10.4187/respcare.09075

53. Chang Y-C, Wang P-F. Corticosteroids and neuromuscular blockers in development of critical illness neuromuscular abnormalities: a historical review. *J Crit Care.* 2017;37:149-155. doi:10.1016/j.jcrc.2016.09.018

54. Alshahrani M, Alshahri M, Alhazzani W, et al. Corticosteroids and neuromuscular blockers in critical illness: a systematic review. *Respir Care.* 2020;65(10):1362-1371. doi:10.4187/respcare.09075

55. Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, González-González JG, Tame-Teixa AL. Steroid hyperglycaemia: Prevalence, early detection and therapeutic recommendations: a narrative review. *World J Diabetes.* 2015;6(8):1073-1081. doi:10.4239/wjvd.v6.i8.1073

56. Perez A, Jansen-Chaparro S, Saiqi I, Bernal-Lopez MR, Milhazes I, Gomez-Huelgas R. Glucocorticoid-induced hyperglycaemia. *J Diabetes.* 2014;6(1):9-20. doi:10.1111/1753-0407.12090

57. Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, González-González JG, Tame-Teixa AL. Steroid hyperglycaemia: Prevalence, early detection and therapeutic recommendations: a narrative review. *World J Diabetes.* 2015;6(8):1073-1081. doi:10.4239/wjvd.v6.i8.1073
76. Sheehy L. Considerations for postacute rehabilitation for survivors of COVID-19. JIMR Public Health Surveil. 2020;6(2):e19462. doi:10.2196/19462

77. Lee DTS, Wing YK, Leung HCM, et al. Factors associated with psychosis among patients with severe acute respiratory syndrome: a case-control study. Clin Infect Dis. 2004;39(8):1247-1249. doi:10.1086/424016

78. Griffiths MJD, McAuley DF, Perkins GD, et al. Guidelines on the management of acute respiratory distress syndrome. BMJ Open Respir Res. 2019;6(1):e000420. doi:10.1136/bmjresp-2019-000420

79. Alhazzani W, Evans L, Alshamsi F, et al. Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update. Crit Care Med. 2021;49(3):e219. doi:10.1097/CCM.0000000000004899

80. The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330-1341. doi: 10.1001/jama.2020.17023

81. Mammen MJ, Aryal K, Alhazzani W, Alexander PE. Corticosteroids for patients with acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials. Pol Arch Intern Med. 2020;130(4):276-286. doi:10.20452/pa mw.15239

82. Vasquez CR, Gupta S, Miano TA, et al. Identification of distinct clinical subphenotypes in critically ill patients with COVID-19. Chest. 2021;160(3):929-943. doi:10.1016/j.chest.2021.04.062

How to cite this article: Landolf KM, Lemieux SM, Rose C, et al. Corticosteroid use in ARDS and its application to evolving therapeutics for coronavirus disease 2019 (COVID-19): A systematic review. Pharmacotherapy. 2022;42:71–90. doi:10.1002/phar.2637